Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas

Dario Sangiolo, Giulia Mesiano, Loretta Gammaitoni, Valeria Leuci, Maja Todorovic, Lidia Giraudo, Cristina Cammarata, Carmine Dell'Aglio, Lorenzo D'Ambrosio, Alberto Pisacane, Ivana Sarotto, Sara Miano, Ivana Ferrero, Fabrizio Carnevale-Schianca, Ymera Pignochino, Francesco Sassi, Andrea Bertotti, Wanda Piacibello, Franca Fagioli, Massimo AgliettaGiovanni Grignani

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Unresectable metastatic bone sarcoma and soft-tissue sarcomas (STS) are incurable due to the inability to eradicate chemoresistant cancer stem-like cells (sCSC) that are likely responsible for relapses and drug resistance. In this study, we investigated the preclinical activity of patient-derived cytokine-induced killer (CIK) cells against autologous bone sarcoma and STS, including against putative sCSCs. Tumor killing was evaluated both in vitro and within an immunodeficient mouse model of autologous sarcoma. To identify putative sCSCs, autologous bone sarcoma and STS cells were engineered with a CSC detector vector encoding eGFP under the control of the human promoter for OCT4, a stem cell gene activated in putative sCSCs. Using CIK cells expanded from 21 patients, we found that CIK cells efficiently killed allogeneic and autologous sarcoma cells in vitro. Intravenous infusion of CIK cells delayed autologous tumor growth in immunodeficient mice. Further in vivo analyses established that CIK cells could infiltrate tumors and that tumor growth inhibition occurred without an enrichment of sCSCs relative to control-treated animals. These results provide preclinical proof-of-concept for an effective strategy to attack autologous sarcomas, including putative sCSCs, supporting the clinical development of CIK cells as a novel class of immunotherapy for use in settings of untreatable metastatic disease.

Original languageEnglish
Pages (from-to)119-129
Number of pages11
JournalCancer Research
Volume74
Issue number1
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Cytokine-Induced Killer Cells
Sarcoma
Bone and Bones
Neoplasms
Neoplastic Stem Cells
Growth
Drug Resistance
Intravenous Infusions
Immunotherapy
Stem Cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. / Sangiolo, Dario; Mesiano, Giulia; Gammaitoni, Loretta; Leuci, Valeria; Todorovic, Maja; Giraudo, Lidia; Cammarata, Cristina; Dell'Aglio, Carmine; D'Ambrosio, Lorenzo; Pisacane, Alberto; Sarotto, Ivana; Miano, Sara; Ferrero, Ivana; Carnevale-Schianca, Fabrizio; Pignochino, Ymera; Sassi, Francesco; Bertotti, Andrea; Piacibello, Wanda; Fagioli, Franca; Aglietta, Massimo; Grignani, Giovanni.

In: Cancer Research, Vol. 74, No. 1, 01.01.2014, p. 119-129.

Research output: Contribution to journalArticle

Sangiolo, Dario ; Mesiano, Giulia ; Gammaitoni, Loretta ; Leuci, Valeria ; Todorovic, Maja ; Giraudo, Lidia ; Cammarata, Cristina ; Dell'Aglio, Carmine ; D'Ambrosio, Lorenzo ; Pisacane, Alberto ; Sarotto, Ivana ; Miano, Sara ; Ferrero, Ivana ; Carnevale-Schianca, Fabrizio ; Pignochino, Ymera ; Sassi, Francesco ; Bertotti, Andrea ; Piacibello, Wanda ; Fagioli, Franca ; Aglietta, Massimo ; Grignani, Giovanni. / Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. In: Cancer Research. 2014 ; Vol. 74, No. 1. pp. 119-129.
@article{7f670585f2ff41459d028cdae8f0258c,
title = "Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas",
abstract = "Unresectable metastatic bone sarcoma and soft-tissue sarcomas (STS) are incurable due to the inability to eradicate chemoresistant cancer stem-like cells (sCSC) that are likely responsible for relapses and drug resistance. In this study, we investigated the preclinical activity of patient-derived cytokine-induced killer (CIK) cells against autologous bone sarcoma and STS, including against putative sCSCs. Tumor killing was evaluated both in vitro and within an immunodeficient mouse model of autologous sarcoma. To identify putative sCSCs, autologous bone sarcoma and STS cells were engineered with a CSC detector vector encoding eGFP under the control of the human promoter for OCT4, a stem cell gene activated in putative sCSCs. Using CIK cells expanded from 21 patients, we found that CIK cells efficiently killed allogeneic and autologous sarcoma cells in vitro. Intravenous infusion of CIK cells delayed autologous tumor growth in immunodeficient mice. Further in vivo analyses established that CIK cells could infiltrate tumors and that tumor growth inhibition occurred without an enrichment of sCSCs relative to control-treated animals. These results provide preclinical proof-of-concept for an effective strategy to attack autologous sarcomas, including putative sCSCs, supporting the clinical development of CIK cells as a novel class of immunotherapy for use in settings of untreatable metastatic disease.",
author = "Dario Sangiolo and Giulia Mesiano and Loretta Gammaitoni and Valeria Leuci and Maja Todorovic and Lidia Giraudo and Cristina Cammarata and Carmine Dell'Aglio and Lorenzo D'Ambrosio and Alberto Pisacane and Ivana Sarotto and Sara Miano and Ivana Ferrero and Fabrizio Carnevale-Schianca and Ymera Pignochino and Francesco Sassi and Andrea Bertotti and Wanda Piacibello and Franca Fagioli and Massimo Aglietta and Giovanni Grignani",
year = "2014",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-13-1559",
language = "English",
volume = "74",
pages = "119--129",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas

AU - Sangiolo, Dario

AU - Mesiano, Giulia

AU - Gammaitoni, Loretta

AU - Leuci, Valeria

AU - Todorovic, Maja

AU - Giraudo, Lidia

AU - Cammarata, Cristina

AU - Dell'Aglio, Carmine

AU - D'Ambrosio, Lorenzo

AU - Pisacane, Alberto

AU - Sarotto, Ivana

AU - Miano, Sara

AU - Ferrero, Ivana

AU - Carnevale-Schianca, Fabrizio

AU - Pignochino, Ymera

AU - Sassi, Francesco

AU - Bertotti, Andrea

AU - Piacibello, Wanda

AU - Fagioli, Franca

AU - Aglietta, Massimo

AU - Grignani, Giovanni

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Unresectable metastatic bone sarcoma and soft-tissue sarcomas (STS) are incurable due to the inability to eradicate chemoresistant cancer stem-like cells (sCSC) that are likely responsible for relapses and drug resistance. In this study, we investigated the preclinical activity of patient-derived cytokine-induced killer (CIK) cells against autologous bone sarcoma and STS, including against putative sCSCs. Tumor killing was evaluated both in vitro and within an immunodeficient mouse model of autologous sarcoma. To identify putative sCSCs, autologous bone sarcoma and STS cells were engineered with a CSC detector vector encoding eGFP under the control of the human promoter for OCT4, a stem cell gene activated in putative sCSCs. Using CIK cells expanded from 21 patients, we found that CIK cells efficiently killed allogeneic and autologous sarcoma cells in vitro. Intravenous infusion of CIK cells delayed autologous tumor growth in immunodeficient mice. Further in vivo analyses established that CIK cells could infiltrate tumors and that tumor growth inhibition occurred without an enrichment of sCSCs relative to control-treated animals. These results provide preclinical proof-of-concept for an effective strategy to attack autologous sarcomas, including putative sCSCs, supporting the clinical development of CIK cells as a novel class of immunotherapy for use in settings of untreatable metastatic disease.

AB - Unresectable metastatic bone sarcoma and soft-tissue sarcomas (STS) are incurable due to the inability to eradicate chemoresistant cancer stem-like cells (sCSC) that are likely responsible for relapses and drug resistance. In this study, we investigated the preclinical activity of patient-derived cytokine-induced killer (CIK) cells against autologous bone sarcoma and STS, including against putative sCSCs. Tumor killing was evaluated both in vitro and within an immunodeficient mouse model of autologous sarcoma. To identify putative sCSCs, autologous bone sarcoma and STS cells were engineered with a CSC detector vector encoding eGFP under the control of the human promoter for OCT4, a stem cell gene activated in putative sCSCs. Using CIK cells expanded from 21 patients, we found that CIK cells efficiently killed allogeneic and autologous sarcoma cells in vitro. Intravenous infusion of CIK cells delayed autologous tumor growth in immunodeficient mice. Further in vivo analyses established that CIK cells could infiltrate tumors and that tumor growth inhibition occurred without an enrichment of sCSCs relative to control-treated animals. These results provide preclinical proof-of-concept for an effective strategy to attack autologous sarcomas, including putative sCSCs, supporting the clinical development of CIK cells as a novel class of immunotherapy for use in settings of untreatable metastatic disease.

UR - http://www.scopus.com/inward/record.url?scp=84892759435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892759435&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-1559

DO - 10.1158/0008-5472.CAN-13-1559

M3 - Article

C2 - 24356422

AN - SCOPUS:84892759435

VL - 74

SP - 119

EP - 129

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 1

ER -